共 50 条
- [21] Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker CorrelatesJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) : 1889 - 1894Choueiri, Toni K.Jacobus, SusannaBellmunt, JoaquimQu, AngelaAppleman, Leonard J.Tretter, ChristopherBubley, Glenn J.Stack, Edward C.Signoretti, SabinaWalsh, MegharaSteele, GraemeHirsch, MichelleSweeney, Christopher J.Taplin, Mary-EllenKibel, Adam S.Krajewski, Katherine M.Kantoff, Philip W.Ross, Robert W.Rosenberg, Jonathan E.
- [22] Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladderJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)Wright, Jonathan LawrenceLee, FranklinHarris, William ProctorCheng, Heather H.Zhao, SongChampion, ThomasGore, John L.Dean, JamesPorter, Michael P.Yu, Evan Y.
- [23] Methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) versus gemcitabine, and cisplatin (GC) as neoadjuvant chemotherapy in muscle-invasive bladder cancer, a systematic review and meta-analysis.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Benkhadra, RaedNayfeh, TarekPatibandla, Naga Sai KrishnaPeterson, ChelseaProkop, LarryAlhalabi, OmarMurad, M. HassanMao, Shifeng
- [25] Neoadjuvant Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy for Muscle-Invasive Urothelial Cancer: Large, Single-Center Analysis of Consecutive Patients' DataCANCERS, 2025, 17 (02)Kwinta, LukaszKonopka, KamilOkon, KrzysztofLobacz, MateuszChlosta, PiotrDudek, PrzemyslawBuda-Nowak, AnnaPotocki, PawelWysocki, Piotr J.
- [26] Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancerJOURNAL OF UROLOGY, 2005, 174 (01): : 80 - 84Nieuwenhuijzen, JABex, AMeinhardt, WKerst, JMSchornagel, JHVan Tinteren, HHorenblas, S
- [27] Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-AnalysisCANCERS, 2021, 13 (11)Chung, Doo YongKang, Dong HyukKim, Jong WonHa, Jee SooKim, Do KyungCho, Kang Su
- [28] Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder CancerONCOLOGY-NEW YORK, 2022, 36 (01): : 30 - 31Gong, Jun
- [29] Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder CancerCANCER RESEARCH AND TREATMENT, 2016, 48 (03): : 1084 - 1091Narayan, VivekMamtani, RonacKeefe, StephenGuzzo, ThomasMalkowicz, S. BruceVaughn, David J.
- [30] Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder CancerADVANCES IN UROLOGY, 2013, 2013Lee, Franklin C.Harris, WilliamCheng, Heather H.Shenoi, JaideepZhao, SongWang, JunfengChampion, ThomasIzard, JasonGore, John L.Porter, MichaelYu, Evan Y.Wright, Jonathan L.